Literature DB >> 3376136

Ganglioside treatment of vincristine-induced neuropathy. An electrophysiologic study.

G Favaro1, F Di Gregorio, C Panozzo, M G Fiori.   

Abstract

A 5-week treatment with vincristine (0.20 or 0.25 mg/kg, i.v., once/week) in the rabbit produced a peripheral neuropathy characterized by both morphologic and electrophysiologic alterations. In particular, electrophysiologic recordings demonstrated that the amplitude, area and conduction velocity of compound action potential (CAP) were consistently reduced in a dose-dependent manner. The simultaneous daily administration of 50 mg/kg ganglioside mixture counteracted significantly this functional impairment, area and amplitude of the monophasic CAP being maintained closer to control values. These results suggest that the loss of functional nerve fibers can be reduced, in vincristine-induced neuropathy, by ganglioside treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3376136     DOI: 10.1016/0300-483x(88)90015-7

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  4 in total

1.  Vincristine-induced neuropathy in rat: electrophysiological and histological study.

Authors:  Feras M H Ja'afer; Farqad B Hamdan; Faiq H Mohammed
Journal:  Exp Brain Res       Date:  2006-05-31       Impact factor: 1.972

2.  Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma.

Authors:  S Koeppen; C C P Verstappen; R Körte; M E Scheulen; D Strumberg; T J Postma; J J Heimans; P C Huijgens; B Kiburg; K Renzing-Köhler; H C Diener
Journal:  J Cancer Res Clin Oncol       Date:  2004-01-16       Impact factor: 4.553

3.  Efficacy of ganglioside treatment in reducing functional alterations induced by vincristine in rabbit peripheral nerves.

Authors:  F Di Gregorio; G Favaro; C Panozzo; M G Fiori
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Ganglioside-monosialic acid (GM1) for prevention of chemotherapy-induced peripheral neuropathy: a meta-analysis with trial sequential analysis.

Authors:  Shaoyong Wu; Xiaohui Bai; Caixia Guo; Zhimei Huang; Handong Ouyang; Jingxiu Huang; Weian Zeng
Journal:  BMC Cancer       Date:  2021-11-02       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.